Munisha Smalley, Siva Kumar Natarajan, Jayanta Mondal, Douglas Best, David Goldman, Basavaraja Shanthappa, Moriah Pellowe, Chinmayee Dash, Tanmoy Saha, Sachin Khiste, Nithya Ramadurai, Elliot O Eton, Joshua L Smalley, Andrew Brown, Allen Thayakumar, Mamunur Rahman, Kazuya Arai, Mohammad Kohandel, Shiladitya Sengupta, Aaron Goldman
Drug-induced resistance, or tolerance, is an emerging yet poorly understood failure of anticancer therapy. The interplay between drug-tolerant cancer cells and innate immunity within the tumor, the consequence on tumor growth, and therapeutic strategies to address these challenges remain undescribed. Here, we elucidate the role of taxane-induced resistance on natural killer (NK) cell tumor immunity in triple-negative breast cancer (TNBC) and the design of spatiotemporally controlled nanomedicines, which boost therapeutic efficacy and invigorate "disabled" NK cells...
December 1, 2020: Cancer Research